WHO Sounds Alert Over Acute Scarcity of Obesity Jabs

Fewer than 10% of patients that would benefit from obesity jabs such as Wegovy have access to them, states the global health agency as it releases its inaugural recommendations on the therapies.

Given over a billion people worldwide now classified as obese, it is advocating for more widespread and fairer availability to GLP-1 medication.

Per forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.

"Our new guidance recognises that excess weight is a long-term condition that can be addressed with thorough and lifelong support," said its chief Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and distribution challenges are key barriers to broad availability to the injections that can help people shift considerable weight, says the agency.

Skinny Jab Supply Crisis

Even in the current most favorable case, the production of GLP-1 therapies would only suffice for about 100 million people – less than 10% of those who need them, per the WHO.

The advice urges governments and firms to expand access, via measures including patent sharing.

A patent on semaglutide – the core ingredient of a leading brand – is due to expire in several countries in 2026.

The Way Weight-Loss Drugs Operate

The injections mimick a body's own hormone to reduce digestion speed, reduce hunger and increase the sense of being full so people eat less.

Individuals typically begin shedding pounds in the initial weeks of starting on the weekly injections.

Studies points to users may regain a significant portion a year later of stopping the treatment, because their normal appetite resume.

To be above a healthy weight increases your likelihood for experiencing diseases, including diabetes, cardiovascular issues, brain attack, and specific malignancies.

Obesity concerns individuals in all nations and was associated with millions of fatalities worldwide in 2024, as per the health agency.